Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.72 |
| ▸ | TSHR | P16473 | 1/20 | 0.72 |
| ▸ | THPO | P40225 | 1/20 | 0.72 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.72 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.72 |
| ▸ | CYP19A1 | P11511 | 17/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6573070 | 1.00 | CYP3A4 (0.72) | CYP3A4TSHRTHPOHIF1ATDP1 | |
| SCHEMBL5683847 | 0.87 | CYP3A4 (0.56) | CYP3A4TSHRTHPOHIF1ATDP1 | |
| SCHEMBL5683853 | 0.87 | CYP3A4 (0.56) | CYP3A4TSHRTHPOHIF1ATDP1 | |
| Formestane SCHEMBL14291425 | 0.84 | CYP3A4 (1.00) | CYP3A4TSHRTHPOHIF1ATDP1 | |
| SCHEMBL6573091 | 0.84 | CYP3A4 (1.00) | CYP3A4TSHRTHPOHIF1ATDP1 | |
| Formestane SCHEMBL13838287 | 0.84 | CYP3A4 (1.00) | CYP3A4TSHRTHPOHIF1ATDP1 | |
| Formestane SCHEMBL22891821 | 0.84 | CYP3A4 (1.00) | CYP3A4TSHRTHPOHIF1ATDP1 | |
| Formestane SCHEMBL25717 | 0.84 | CYP3A4 (1.00) | CYP3A4TSHRTHPOHIF1ATDP1 | |
| Formestane SCHEMBL947479 | 0.84 | CYP3A4 (1.00) | CYP3A4TSHRTHPOHIF1ATDP1 | |
| SCHEMBL12394388 | 0.84 | CYP3A4 (1.00) | CYP3A4TSHRTHPOHIF1ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4865766-A | Process for the preparation of 4-amino-androstenedione derivatives | FARMITALIA CARLO ERBA S.R.L. (IT) | 1989-09-12 | — | — | US | claimed |
| EP-1409512-A1 | 20-FLUORO-17(20)-VINYL STEROIDS AS INHIBITORS OF C17-20-LYASE AND 5-ALPHA REDUCTASE | Aventis Pharma S.A. (FR) | 2004-04-21 | — | — | EP | disclosed |
| US-6413951-B2 | ENZYME INHIBITOR | AVENTIS PHARMACEUTICALS, INC. | 2002-07-02 | — | — | US | disclosed |
| US-20020019548-A1 | 20-Fluoro-17(20)-vinyl steroids | AVENTIS PHARMA S.A. (FR) | 2002-02-14 | — | — | US | disclosed |
| WO-2002000681-A1 | 20-FLUORO-17(20)-VINYL STEROIDS AS INHIBITORS OF C17-20-LYASE AND 5-ALPHA REDUCTASE | AVENTIS PHARMA S.A. (FR) | 2002-01-03 | — | — | WO | disclosed |
| EP-0291290-B1 | PROCESS FOR THE PREPARATION OF 4-AMINO-ANDROSTENEDIONE DERIVATIVES | FARMITALIA CARLO ERBA S.r.l. (IT) | 1992-01-22 | — | — | EP | disclosed |
| US-4865766-A | Process for the preparation of 4-amino-androstenedione derivatives | FARMITALIA CARLO ERBA S.R.L. (IT) | 1989-09-12 | — | — | US | disclosed |
| EP-0291290-A1 | Process for the preparation of 4-amino-androstenedione derivatives | FARMITALIA CARLO ERBA S.r.l. (IT) | 1988-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019548-A1 | 20-Fluoro-17(20)-vinyl steroids | CYP17A1, HSD17B11, HSD3B1 | CYP3A4 167/4885TSHR 550/4885THPO 3473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.